Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access advanced solid tumors specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced solid tumors treatment provided free
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types
Sponsor: LigaChem Biosciences, Inc.
Check if you qualify for this advanced solid tumors clinical trial in Los Angeles, CA
If you're searching for advanced solid tumors treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.